Loth, Kevin

Corporate Affairs and Policy - Europe and International Markets, Celgene

Kevin Loth has worked at Celgene since 2007. He is responsible for leading Celgene’s Corporate Affairs Department, encompassing the functions of Communications, Government Relations and Patient Advocacy.
Kevin is a member of the EMEA Management Team and Global Corporate Affairs Leadership Team. Kevin’s role is to lead the EMEA Corporate Affairs Community of Practice; ensuring patients remain at the centre of decision making, supporting Celgene’s growth, and promoting the value of innovation.
Kevin is a member of the EFPIA Healthcare Systems Working Group and IFPMA Rare Disease Committee.
Kevin was the former Vice-Chair of the EBE-EuropaBio Joint Taskforce on Rare Diseases and Orphan Medicinal Products and was an industry representative on the European Union Committee of Experts on Rare Diseases from 2011 to 2013.
These positions have helped establish Celgene as a respected stakeholder, working in collaboration with others to improve patient access to treatments for rare, life threatening and serious debilitating diseases. Prior to joining Celgene, Kevin spent seven years at Novartis; three years as Head of UK Government Relations and four years as Director of European Government Affairs, based in Brussels.
During this time, he was responsible for managing relationships with the European Parliament, European Commission, as well as the official representatives of EU Member States.
Kevin has a PhD in Environmental Epidemiology, an MSc in Environmental Technology from Imperial College, London and an MBA from Manchester Business School. His MBA thesis was on the impact of NICE on the European pharmaceutical industry. Kevin is married with three young children.

(last updated 26.09.2017)